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Abstract  
14-3-3σ is a protein expressed in many epithelial tissues associated with essential cell 
functions including cell-cycle control, apoptosis and cytoskeletal integrity. There is a 
paucity of knowledge of the tumorigenesis of canine renal cell carcinomas (CRCC) and 
the histological origin of this tumor has not been established. This study analyzed the 
expression of 14-3-3σ, Ki67, cytokeratins and vimentin in 40 CRCC. Aberrant 
expression of 14-3-3σ was demonstrated in 15 (38%) cases, and was associated with 
a significantly shorter survival time (p<0.002). In contrast to CRCC, normal kidney did 
not express 14-3-3σ. Ki-67proliferation index did not show utility as a prognostic factor. 
The distal convoluted tubular epithelium in normal kidneys co-expressed cytokeratins 
and vimentin and thus maintenance of this co-expression pattern in CRCC suggests 
that most tumors arise from the distal segment of the nephron. These results suggest 
that 14-3-3σ is a potential negative prognostic factor and a possible therapeutic target. 
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The 14-3-3 family is a group of small, highly conserved and ubiquitously expressed 
acidic proteins with molecular weights between 28–33 kDa. They are found in all 
eukaryotic species and include seven different 14-3-3 protein isoforms in mammalian 
cells, each designated by a Greek letter (beta-β, epsilon-ε, gamma-γ, eta-η, theta-θ, 
sigma-σ, and zeta-ζ). Multiple 14-3-3 ligands are involved in various cellular processes 
including DNA damage signaling, cell proliferation and survival, cytoskeleton 
rearrangement, transcriptional control and cell cycle regulation. Specifically, the ability 
of 14-3-3 proteins to bind and regulate several oncogenic, as well as various tumour 
suppressor gene products, suggests they have a potential role in tumorigenesis.13,17  
Unlike other family members, which are broadly expressed in the brain and play a 
pivotal role in neurodegenerative diseases, 14-3-3σ (also known as stratifin or human 
mammary epithelial marker-1) is only expressed in epithelial cells and is closely 
associated with tumor development. The expression of this isoform was originally 
identified as a response to DNA damage and TP53 activation. TP53 encodes the 
protein p53 which subsequently induces the production of 14-3-3σ in the cytoplasm. 
14-3-3σ is able to bind and sequester specific cyclin-dependent kinases, CDK4, CDK2 
and CDK1 that regulate the G1/S and G2/M cell cycle checkpoints preventing initiation 
of mitosis and allowing DNA repair.14 Furthermore, 14-3-3σ has been shown to play 
an anti-apoptotic role and promote cell survival29 and recently has been identified as a 
promising therapeutic target.2,40 In veterinary medicine, 14-3-3σ has been reported as 
an oncoprotein in canine mammary and urinary bladder carcinomas.34-36 
Carcinomas are the most common canine primary renal tumors comprising 4 different 
histologic patterns (solid [clear cell or chromophobe type], tubular, papillary and 
multilocular cystic)9,19,20 that display heterogeneous biological behaviors and present 
an overall median survival time (MST) ranging from 359-743 days.3,5,9 Clinical outcome 
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is associated with histologic subtype, mitotic index and Cox-2 expression.5 In contrast 
to humans, there is a dearth of knowledge with regards to the mechanisms and 
molecules that contribute to the development and progression of canine renal cell 
carcinomas. Additionally, the histological origin of these tumors in the dog has still not 
been clarified and there is evidence that their immunophenotype differs from the 
human counterpart.8  
In order to elucidate if 14-3-3σ plays a role in CRCC oncogenesis, as has been 
demonstrated for other canine tumors, this study aims to investigate the expression of 
the protein and its association with outcome and with various clinicopathological 
variables, including Ki-67labelling index. Immunohistochemical labelling will be used 
to compare the distribution of two major cell markers (cytokeratins and vimentin) in the 
normal kidney to their expression pattern in tumors to determine the cell of origin of 
CRCC. 
 
Materials and Methods 
 
Case selection 
Cases included in this retrospective study were selected from a previously published 
series of dogs with CRRC that underwent nephrectomy (n=39).5 One case presented 
with metastatic disease and was immediately euthanized and diagnosis was made at 
necropsy; this dog was not included in the survival analysis. A complete medical history 
from dogs containing signalment, clinical presentation, laboratory findings, clinical 
stage, histological diagnosis, use and type of adjuvant therapy and overall MST was 
available. Samples from five normal canine kidneys were used as controls.  
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Histological classification 
Hematoxylin- and eosin-stained tissue sections were histologically classified according 
to the WHO Histological Classification of Tumors of the Urinary System of Domestic 
Animals by three veterinary pathologists (ASB, ALS and SLP).19 In cases of 
disagreement between two or more pathologists, a consensus was reached. To further 
classify the solid tumors into clear cell and chromophobe-type carcinomas, additional 
tissue sections were stained with Hale’s colloidal iron stain. In addition to subtype, 
other histopathological features including mitotic activity index (MAI) (mitoses per 2.37 
mm2)21, presence of necrosis, inflammation and vascular invasion were assessed as 
previously described.5  
 
Immunohistochemistry and evaluation 
Immunohistochemical analysis was performed in forty cases. Four micrometer thick 
fresh-cut tissue sections from formalin-fixed, paraffin-embedded tissue blocks were 
labeled with mouse-monoclonal antibodies against 14-3-3σ (clone 5D7, 1:40, Santa 
Cruz Biotechnology, Heidelberg, Germany), Ki-67(MIB-1, 1:150, Dako, Ely, UK), 
cytokeratins  (clone AE1/ AE3, 1:100, Dako) and vimentin (clone V9, 1:500, Dako) on 
a BondMax Autostainer (Leica, Milton Keynes, UK). 14-3-3σ antibody has been 
previously shown to identify the appropriate canine molecular weight antigens by 
western blot and to cross-react with canine tissues.27,33,36 Heat-induced antigen 
retrieval was performed using a pH 6 buffer (Bond ER1, Leica) for 10 minutes 
(vimentin), 20 minutes (14-3-3σ) and 30 minutes (AE1/AE3) at 90oC and a pH 9 buffer 
(Bond ER2, Leica) for 10 minutes at 90oC for Ki-67. The Bond Polymer Refine 
Detection kit (Leica) was used for visualization with hematoxylin counterstain. As 
positive controls, normal canine urinary bladder (for 14-3-3σ), normal canine skin (for 
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cytokeratins and vimentin) and a hyperplastic lymph node (for Ki-67) were used in 
every assay. All positive controls showed: cytoplasmic immunolabeling of the urinary 
bladder urothelium for 14-3-3σ, nuclear immunolabeling for Ki-67, and cytoplasmic 
immunolabeling for cytokeratins and vimentin. When present, surrounding 
histologically normal renal tissue was used as an internal positive control. Negative 
controls were prepared by replacing the primary antibody with Leica Antibody Diluent 
(Leica) only. A positive reaction was indicated by the presence of distinct brown 
cytoplasmic or nuclear labelling in neoplastic cells.   
Immunoreactivity was independently evaluated by two of the authors (ASB and SLP) 
and discrepancies were discussed jointly on a double-headed microscope. To evaluate 
correlations with clinical features, pathological variables and outcome, positive labeling 
for 14-3-3σ was assessed using a previously published semiquantitative scoring 
system.35 The percentage (1, up to 10%; 2, 11%–50%; 3, 51%–80%; and 4, >80%) 
and the staining intensity (0, negative; 1, weak; 2, moderate; and 3, intense) of positive 
cells was recorded and a total score (TS), ranging from 0 to 12 was calculated by 
multiplying these two parameters for each of the studied cases. The count of Ki-67-
positive cells was performed in 10 high power fields (40X) counting at least 1,000 cells 
for each case, using the TMARKER software.28 Ki-67 expression was evaluated as the 
labeling index and was defined as the percentage of Ki-67-positive cells. For 
cytokeratins and vimentin, positivity was recorded when there was distinct cytoplasmic 
labelling of the neoplastic epithelial cells and scored semiquantitatively (0, negative; 1, 
weakly positive; 2, moderately positive and 3, strongly positive) as previously 
described.12  
 
Statistical analysis 
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Expression of 14-3-3σ, Ki-67, cytokeratins and vimentin were compared with 
histological subtype, MAI, metastasis at diagnosis, necrosis and inflammation. A chi-
squared and a Fisher’s exact test were used for studying categorical variables. Non-
parametric analysis was performed with the Kruskal-Wallis 1-way ANOVA test. Overall 
median survival time was defined as time from nephrectomy for CRCC treatment until 
death. Dogs that were lost to follow-up or still alive at the end of the study period or 
died were censored. 
Survival analysis using the Kaplan-Meier product limit method was conducted to 
estimate disease-related MST, for the whole population of CRCC dogs. To compare 
estimated disease-related MST between categories the logrank test (univariate 
analysis) was employed. Multivariate analysis using Cox-regression analysis was 
performed to demonstrate combined predictor variables found significant in univariate 
analysis. All statistical analyses were carried out using SPSS software (version for 
Windows 22.0 Armonk, IBM Corp., NY, USA). In all comparisons, P <0.05 was 
accepted as defining statistical significance. 
 
Results 
 
Clinical findings 
For the 39 dogs with clinical follow-up, the median age at diagnosis was 8 years (range, 
2–12 years). There was a male to female ratio of 1.05:1, including 20 males (9 intact) 
and 19 females (5 intact). Breed distribution amongst dogs was as follows: 12 cross 
breeds, 7 Labrador Retrievers, 5 Boxers, 3 Golden Retrievers, 2 German Shepherds, 
2 Dalmatians and one each of Cocker Spaniel, Rottweiler, Weimaraner, Japanese 
Akita, Galgo Español, Bullmastiff, English Bulldog and Collie (Supplemental Table S1).  
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The overall median survival time (MST) for dogs diagnosed with RCC was 540 days 
(95% confidence interval [CI], 407–673). Of the 39 dogs, 29 were dead (74%) at the 
end of the data collection period, 8 (21%) were alive and 2 (5%) were lost to follow-up. 
Death due to neoplastic disease occurred in 18/39 dogs (46%). Death was 
documented as unrelated to RCC in 5 (13%) and of unknown cause in 6 dogs (15%).  
 
The most commonly reported presenting signs were weight loss in 15 dogs (38%), 
hematuria in 12 dogs (31%), inappetence or anorexia in 11 dogs (28%) and lethargy 
in 8 dogs (20%). A palpable abdominal mass was evident on physical examination in 
17 dogs (43%). In 3 cases (8%), the renal tumor was an incidental finding during a 
health screening or staging prior to surgery. Other less common presenting complaints 
included, vomiting, abdominal pain and diarrhea. For the 18 cases in which tumor size 
was provided, the average size was 10.5 cm in largest diameter with a range of 5 to 
16 cm.   
 
Histological findings 
Forty RCC cases were available for assessment. Following histological examination 
these were categorized as tubular (n=21, 53%), papillary (n=9, 22%) or solid (n=10, 
25%). Within the group of tumors exhibiting a tubular pattern, 12 out of 21 (57%) cases 
were well-differentiated (composed of easily recognizable tubules formed by cells with 
mild to moderate atypia) and 9 out of 21 (43%) poorly-differentiated (composed of 
closely-packed sheets of cells with rare tubules formed by epithelial cells with marked 
atypia). Using colloidal iron stain the solid group was subclassified into chromophobe 
RCC (n=9, 90%) that were positive with colloidal iron stain, and clear cell RCC (n=1, 
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10%) that exhibited large cytoplasmic vacuoles and eccentric nuclei and were negative 
with colloidal iron stain.  
 
14-3-3 expression 
14-3-3 expression was not detected in histologically normal canine kidney  (glomeruli, 
proximal convoluted tubules, distal convoluted tubules, loop of Henle and collecting 
ducts) surrounding carcinomatous areas (n = 12) or in two normal canine kidney 
samples used as controls (Fig.1). In contrast, compressed and reactive convoluted 
tubules, located at the periphery of renal carcinomas, occasionally displayed moderate 
to intense cytoplasmic immunoreaction (Fig. 1 inset), but these positive areas were not 
considered in the generation of a TS. As there was no protein labelling in normal 
kidney, cases with a TS ≥ 1 were considered positive and consequently to neo-express 
14-3-3. Within the tumors, positive protein expression occurred in 15/40 RCC (38%), 
(12 tubular, 2 papillary and 1 solid), with TS ranging from 1 to 12 (median 5.2), and 
26/40 cases were negative (62%). The positive to negative ratio between the three 
histological tumour subtypes (tubular, papillary and solid) were 12:9, 2:7 and 1:9. 
Seven cases had a TS < 3, considered as low 14-3-3-expression (Fig. 2) and 8 cases 
had a TS ≥ 4, considered as high 14-3-3-expression (Figs. 3 and 4). Of this latter 
group 6 cases were tubular, 2 cases were papillary and one case was solid (clear cell 
type). Two tubular and one papillary carcinoma showed the highest TS (12). The 
predominant staining pattern was cytoplasmic, but in 13 of 15 positive cases (86%) the 
nucleus also exhibited positive labelling. There were no cases with an exclusive 
nuclear staining pattern. In all positive cases the immunoreaction varied from those 
with heterogeneous staining, characterized by groups of cells without expression or 
mildly positive, or cases with multifocal strongly positive cells, to cases with diffuse and 
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intense staining. Within the positive cases, mitotic figures including those with bizarre 
morphology exhibited moderate to strong immunopositivity to 14-3-3σ (Fig. 3 inset). 
Positive cases that contained areas with clusters and solitary bizarre neoplastic cells 
at the front of invasion into the adjacent renal parenchyma and vascular invasion within 
lymphatics showed intense expression of the protein (Fig. 4 inset). Furthermore, one 
of the positive cases had tissue from a lung metastasis available that was positively 
labelled. Stromal tissue, fibroblasts and areas of necrosis were not immunolabeled for 
14-3-3σ. 
 
Ki-67 expression  
Ki-67 was detected only in cell nuclei without cytoplasmic immunolabeling in any of the 
samples. Normal canine kidney did not express Ki-67 and histologically normal kidney 
adjacent to carcinomas sporadically showed positive cells in the tubular lining 
epithelium. Ki-67 proliferative index (PI) ranged from 0.0% to 56.0% (mean 15.7%) of 
cells. The mean Ki-67 values for each tumor type, tubular, papillary and solid were 
20.2%, 14.5% and 3.0% respectively. In 16 of 40 (40%) cases there was no 
immunolabeling for Ki-67. There was no correlation between Ki-67 expression and 
mitotic activity index (P > 0.05). 
 
Cytokeratins and vimentin expression 
In normal canine kidney and in the non-neoplastic renal tissue of the cases with 
carcinoma, the cytokeratin cocktail (which immunoreacts with keratins 1 and 2, 3, 4, 5, 
6, 7, 8, 10, 13, 14, 15 16 and 19) labelled the epithelial cells forming the distal 
convoluted tubule and the collecting tubule and duct, while the proximal convoluted 
tubules and the glomeruli were negative (Fig. 5). Variable proportions of neoplastic 
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cells were immunolabeled in 33/40 (82.5%) cases whereas 7 (17.5%) cases were 
negative. Within the positive cases, 15 (45.5%) were moderately to strongly positive 
and 18 (54.5%) were weakly positive in randomly distributed cell clusters. The staining 
pattern was mainly cytoplasmic and diffuse to finely granular, with frequent 
membranous highlighting (Fig. 6).  
In normal renal parenchyma, vimentin was expressed in glomerular endothelial cells, 
interlobular arteries and veins, peritubular capillaries, vasa recta and the interstitium 
as well as in epithelial cells lining distal convoluted tubules (Fig. 7). In CRCC, vimentin 
was expressed in neoplastic epithelial cells in 34 cases (85%) while 6 cases (15%) did 
not express this marker. Of the positive cases, 26 (76.5%) were moderately to strongly 
positive (Fig. 8) and 8 (23.5%) were weakly positive.  
Of the 40 cases, 27 (67.5%) co-expressed cytokeratins and vimentin to some extent, 
7 cases (17.5%) were cytokeratins negative and vimentin positive, 6 cases (15%) were 
cytokeratins positive and vimentin negative.  
 
Statistical analysis   
In univariate analysis, there was a statistically significant association between high 14-
3-3σ-expression (TS > 4) and a shorter survival time (P = 0.002; (Fig. 9). Furthermore, 
shorter survival time was significantly associated with a high (% = 3-4) percentage of 
positive cells (P = 0.001), and high stain intensity (stain intensity = 2-3; P = 0.000). A 
higher 14-3-3σ TS was positively correlated with the poorly-differentiated tubular 
subtype (P = 0.03) and with a higher (> 30) mitotic activity index (P = 0.003). 
Furthermore, in multivariate analysis, 14-3-3σ-expression remained an independent 
predictor of prognosis (P = 0.013). 14-3-3σ expression was not correlated with 
metastasis at the time of diagnosis, necrosis or type of inflammation, nor with Ki-67, 
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vimentin or cytokeratins expression (P > 0.05). No association was observed between 
Ki-67 index and MST.  
 
Discussion 
In the present study, the expression and prognostic significance of various markers of 
cell proliferation, tumor progression and cell characterization were investigated in a 
large case series of canine RCC. To the author’s knowledge this is the first analysis of 
14-3-3σ in canine RCC, and the first evidence that this protein may be a significant 
prognostic factor in canine neoplasms. 
14-3-3σ expression has become the focus of much research in human medicine. The 
levels of mRNA, protein expression and methylation status have been studied in a 
variety of human cancers.7,22,32,39 As 14-3-3σ can be induced in a p53-dependent 
manner, preventing mitotic catastrophe, and because its expression is silenced in 
various cancers, such as breast and head and neck carcinoma, it has been regarded 
as a tumor suppressor.6,18 Subsequent studies have suggested that its role in 
tumorigenesis is tumor-dependent, as an increasing number of investigations have 
found over-expression and neo-expression of the protein being associated with 
malignancy.16,23,32,39 Similarly, the relevance of this protein as a tissue differentiation 
marker and as an oncoprotein has been reported in canine mammary and urinary 
bladder carcinomas.34-36 In the current study, immunohistochemical analysis revealed 
the absence of 14-3-3σ immunolabelling in normal kidney and is in accordance with 
previous studies using western blot and immunohistochemistry in both humans and 
dogs.22,24,33,36 Interestingly, 14-3-3σ was neo-expressed in 37.5% CRCC which is more 
than double the 16.4% described in human RCC.22 Additionally, positive cases that 
had vascular invasion showed positive labeling in embolic neoplastic cells. While in 
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humans the role of 14-3-3σ remains to be confirmed, we have demonstrated that its 
neo-expression in a subset of CRCC is significantly associated with a shorter survival 
time and is an independent prognostic factor. These results are compatible with 
previous studies in human and canine mammary basal carcinomas, characterized by 
a poor prognosis, that also over-express 14-3-3σ.16,36 It has now been established that 
14-3-3σ can promote lung, liver and pancreatic carcinomas.31,32,38,39 Similar to our 
findings, these tumors arise from tissues that do not constitutively express the protein. 
These findings could support the hypothesis that a mutant form of 14-3-3σ, which 
retains anti-apoptotic and proliferative abilities, favors invasion and metastasis, but 
lacks tumor suppressive activity of the wild type protein, may be produced during 
tumorigenesis. Further studies, analyzing ligands of 14-3-3σ and possible mutations 
are required to clarify its precise role in canine RCC.   
 
The histological origin of canine RCC has not been established. In a previous study12  
including tubulopapillary, papillary, papillary-cystic, sarcomatoid and solid variants, all 
cases were positive for uromodulin, also known as Tamm-Horsfall glycoprotein, which 
is exclusively synthesized in the kidney.10 It was suggested that, because bovine renal 
cell tumors were also positive for uromodulin15, the origin of canine RCC was most 
likely the distal convoluted tubule. However, the bovine study also reported that in the 
normal bovine kidney, uromodulin was present in epithelial cells of both the proximal 
and the distal convoluted tubule and, consequently, it was not possible to establish the 
histogenesis of RCC with this antibody. In the current study we attempted to provide 
insights into the origin of CRCC by immunohistochemistry for broad-spectrum keratin 
(AE1/AE3) and vimentin in both normal and canine RCC. To the best of our knowledge 
the expression pattern of vimentin and cytokeratins in normal kidney in comparison 
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with renal carcinomas has not been studied to date. This comparison is essential in 
order to validate the use of a given antibody as a differentiation marker as this allows 
pathologists to identify if its expression is modified (the antigen may be lost, under- or 
over-expressed or even neo-expressed) in a neoplasm.27 Interestingly, here we show 
that cytokeratins and vimentin are co-expressed in the distal convoluted tubule and, 
for cytokeratins, this expression extends to the collecting tubule and duct. The co-
expression was preserved in 67.5% of the tumors. Vimentin, a marker of mesenchymal 
cells, is expressed in a large proportion of canine RCC and it has been proposed that 
this could represent the acquisition of an epithelial to mesenchymal phenotype.12 
However, given we demonstrated the co-expression of cytokeratins and vimentin in 
the normal distal convoluted tubule epithelium, this supports the hypothesis of this cell 
type as the possible origin of canine RCC. This would be in agreement with the above 
study that used uromodulin expression to support the same hypothesis.12 In humans, 
clear cell RCC account for 70% to 80% of renal carcinomas and papillary carcinoma is 
second in frequency accounting for 10% to 15% of renal carcinomas. These tumors 
share a similar immunoprofile, and most of them express cytokeratins, vimentin and 
CD10 (a marker of proximal convoluted tubules) and are negative for CD117 (positive 
in chromophobe carcinomas). Based on this combination of markers, it is known that 
clear cell RCC arise from proximal convoluted tubules.30,37 In addition, papillary 
carcinomas are thought to arise from distal convoluted tubules.1 Taken together, these 
data suggest that many canine RCC arise from a different segment of the nephron 
than that of human RCC. 
 
Ki-67 protein is expressed in all active phases of the cell cycle (G1, S, G2, and M 
phases) and is a well-documented marker of cell proliferation in different malignancies. 
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Although there was no significant correlation between Ki-67 expression and 
clinicopathological features, the Ki-67 index tended to be higher in 14-3-3σ-positive 
cases. In 40% of cases there was no immunolabeling for Ki-67, nonetheless these 
tissues were reactive for cytokeratins and vimentin. One explanation for this lack of 
labeling may reside in different sensitivity to fixation and it is known that fixation times 
can affect some antigens more than others. There is a single case report of a 
metastatic canine renal cell carcinoma that labelled with Ki-67 but these authors did 
not specify the source of the antibody or give a labeling index.4 In human RCC there 
are conflicting results regarding Ki-67. In one study it served as an independent 
predictor of oncological outcomes in patients with localized clear-cell renal cell 
carcinoma11 while in another there was no correlation between grade, stage and 
outcome.26 Overall it seems that Ki-67 is not yet recognized as a reliable predictor of 
prognosis for RCC.25     
 
In summary, this study shows for the first time that 14-3-3σ protein is neo-expressed 
in a significant number of canine RCC and its presence is positively associated with a 
shorter survival time. Furthermore, it seems that in contrast to humans, most canine 
RCC may arise from distal segments of the nephron.  
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Figure legends 
 
Figures 1-4. Kidney, dog. Immunohistochemistry for 14-3-3σ protein. Figure 1. 
Normal renal parenchyma does not express 14-3-3σ protein. Inset: Occasional non-
neoplastic (reactive) renal tubules, immediately adjacent to a tumor, show intense 
immunoreaction. Figure 2. A well-differentiated tubular canine renal cell carcinoma 
(CRCC) with multifocal weak immunoreaction (total score, TS = 3). Figure 3. A poorly-
differentiated tubular CRCC with intense expression (TS = 12). Inset: Neoplastic cells 
have both cytoplasmic and nuclear labeling. Note the immunolabeled mitotic figure 
(arrow). Figure 4. A well-differentiated tubular CRCC infiltrating the stroma with 
labeling of neoplastic cells but non-labelling in areas of necrosis (arrows). (TS = 12). 
Inset: Immunolabeling of neoplastic cells within lymphatic vessels. 
 
  
 20 
 
Figures 5 and 6. Kidney, dog. Immunohistochemistry for cytokeratins. Figure 5. In 
normal renal parenchyma, cytokeratins are expressed in distal convoluted tubules 
(arrows). Proximal convoluted tubules are negative. Figure 6. A well-differentiated 
tubular renal cell carcinoma with intense cytoplasmic labelling. Figures 7 and 8. 
Kidney, dog. Immunohistochemistry for vimentin. Figure 7. In normal renal 
parenchyma vimentin is expressed in the interstitium, glomerular capillaries and 
epithelial cells of distal convoluted tubules (arrows). Proximal convoluted tubules are 
negative. Figure 8. A well-differentiated tubular renal cell carcinoma with intense 
cytoplasmic labelling. 
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Figure 9. Kaplan-Meier survival curve for overall median survival time according to 14-
3-3σ total score (TS). A TS greater than 4 (solid line) is significantly associated with a 
shorter survival time (P = 0.002). Median survival time (MST). 
 
 
